EMA and industry brainstorm on dearth of new Alzheimer's drugs
This article was originally published in SRA
Executive Summary
The European Medicines Agency is working with companies with an interest in Alzheimer's disease in an effort to determine what prevented them from translating potential new products they were developing into marketing authorization applications (MAAs).